← Leaderboards
Ganesh V Raj
University Of Texas Hlth Science Center
$2,616,233
Attributed
$6,329,161
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2018–23$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,329,161 · 3
By mechanism
R01$4,331,575 · 2
R44$1,997,586 · 1
Top collaborators
- Ratna K Vadlamudi11 shared
- Jung-Mo Ahn2 shared
- Sharron Erna Gargosky2 shared
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Kristin Ann Altwegg$51,460
- David Kadosh$7,861,382
- David C Glahn$22,657,223
- Adriana Baker$42,070
Others in their field
Other Emerging Leaders on “Resistance”
- John Damon Chodera · Sloan-Kettering Inst Can Research$56,843,703
- Urs Ochsner · Crestone, Inc.$40,390,611
- Ryan Cirz · Revagenix, Inc.$40,209,479
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Michael Dignam · National Institute Of Allergy And Infectious Diseases$30,845,607
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$24,789,028
Research focus
ResistancePharmaceutical PreparationsIn VivoXenograft ProcedureGrowthEfficacy TestingTumorToxic EffectIn VitroMolecularClinical TrialsAnalogCell LinePharmacologyMolecular SubtypesNeoplasm MetastasisMediatingDesignMalignant NeoplasmsNovel TherapeuticsCancer EtiologyApoptosisLeadEstrogen Receptors
Grant awards (11)
Enhancing endoplasmic reticulum stress in ovarian cancer$625,549
R01 · FY2023 · CA
Targeting mutant estrogen receptor driven breast cancers$1,015,476
R44 · FY2022 · CA · contact PI
Enhancing endoplasmic reticulum stress in ovarian cancer$666,952
R01 · FY2022 · CA
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$574,038
R01 · FY2022 · CA
Targeting mutant estrogen receptor driven breast cancers$982,110
R44 · FY2021 · CA · contact PI
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$585,712
R01 · FY2021 · CA
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$585,752
R01 · FY2020 · CA
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$568,179
R01 · FY2019 · CA
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$74,623
R01 · FY2019 · CA
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$612,002
R01 · FY2018 · CA
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$38,768
R01 · FY2018 · CA